- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Dublin Today
By the People, for the People
Alkermes Initiates Phase 3 Trials for Narcolepsy Treatment
The pharmaceutical company has launched a clinical program to evaluate a new drug for the sleep disorder.
Apr. 1, 2026 at 6:02pm
Got story updates? Submit your updates here. ›
Alkermes plc, a biopharmaceutical company, has announced the initiation of the Brilliance Studies, a phase 3 clinical program evaluating the safety and efficacy of a new treatment for narcolepsy. The studies will assess the investigational drug alixorexton for managing the symptoms of the sleep disorder.
Why it matters
Narcolepsy is a chronic neurological condition that can significantly impact a person's quality of life. Current treatments have limitations, so the development of new therapeutic options is important for improving patient outcomes. Alkermes' phase 3 trials represent a key milestone in potentially bringing a new narcolepsy drug to market.
The details
The Brilliance Studies will evaluate the safety and efficacy of alixorexton, Alkermes' investigational treatment for narcolepsy. The phase 3 program will assess the drug's ability to manage the debilitating symptoms of the sleep disorder, including excessive daytime sleepiness and cataplexy.
- Alkermes announced the initiation of the Brilliance Studies on April 1, 2026.
The players
Alkermes plc
A biopharmaceutical company that develops medicines for the treatment of central nervous system disorders, oncology, and other chronic health conditions.
Alixorexton
Alkermes' investigational drug for the treatment of narcolepsy, which is currently in phase 3 clinical trials.
The takeaway
The initiation of Alkermes' phase 3 Brilliance Studies represents a significant step forward in the development of a potential new treatment option for the millions of people living with the debilitating symptoms of narcolepsy.
